Related Experiment Video
Updated: Jun 8, 2026
13:38
Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells
Published on: January 18, 2017
Aspirin resistance: fact or fiction?
Dinaldo Cavalcanti de Oliveira1, Rogerio Ferreira Silva, Diego Jantsk Silva
1Hospital do Coração, Brazil.
Arquivos Brasileiros De Cardiologia
|October 15, 2010
Summary
Aspirin effectively reduces cardiovascular events, but some patients show resistance. Aspirin resistance, defined by lab tests or clinical events, is linked to a 3.8 times higher risk of cardiovascular events.
Area of Science:
- Cardiology
- Pharmacology
- Clinical Research
Background:
- Aspirin use in cardiovascular disease (CVD) is linked to a 22% reduction in mortality and ischemic events.
- Recurrent cardiovascular events in patients on aspirin therapy suggest potential aspirin resistance.
- Aspirin resistance is a growing concern in managing patients with cardiovascular disease.
Purpose of the Study:
- To define and explore the phenomenon of aspirin resistance in patients with cardiovascular disease.
- To investigate the clinical implications and laboratory definitions of aspirin resistance.
- To quantify the increased risk of cardiovascular events associated with aspirin resistance.
Main Methods:
- Meta-analysis of clinical studies involving patients with cardiovascular disease on aspirin therapy.
- Definition of clinical aspirin resistance based on recurrent cardiovascular events.
- Definition of laboratory aspirin resistance based on persistent platelet aggregation tests.
Main Results:
- Aspirin therapy is associated with a 22% decrease in death rates and ischemic vascular events.
- A subset of patients on regular aspirin treatment experiences recurrent cardiovascular events.
- Laboratory tests reveal persistent platelet aggregation in aspirin-resistant individuals.
- Aspirin-resistant patients exhibit a 3.8-fold increased risk of cardiovascular events compared to non-resistant patients.
Conclusions:
- Aspirin resistance is a clinically significant phenomenon in cardiovascular disease management.
- Both clinical and laboratory evidence highlight the reduced efficacy of aspirin in resistant patients.
- Identifying and addressing aspirin resistance may improve outcomes for patients with cardiovascular disease.
Related Concept Videos
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:25Mechanism of Antibiotic Resistance in MRSA
Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and acquisition...
01:30Development of Antibiotic Resistance
Antibiotic resistance is a major public health concern that arises when bacteria evolve mechanisms to withstand the effects of antibiotic treatments. This resistance can be intrinsic, acquired through genetic mutations, or transferred between bacteria via horizontal gene transfer. The development of antibiotic resistance poses significant challenges in treating bacterial infections and necessitates ongoing research to develop new therapeutic strategies.Intrinsic resistance occurs when bacterial...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:25Clinical Significance of Antibiotic Resistance
Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within the One...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...